Table 3.
Drug prescribing in eligible study individuals at baseline.
| Drug | Control (N=1299), n (%) |
Intervention (N=1422), n (%) |
Total (N=2721), n (%) |
P value |
| Long-acting insulin | 225 (17.32) | 268 (18.85) | 493 (18.12) | .30 |
| Short-acting insulin | 92 (7.08) | 123 (8.65) | 215 (7.90) | .13 |
| Metformin | 926 (71.29) | 971 (68.28) | 1897 (69.72) | .09 |
| Sulphonylurea | 422 (32.49) | 434 (30.52) | 856 (31.46) | .27 |
| Dipeptidyl peptidase-4 (DPP-4) | 205 (15.78) | 228 (16.03) | 433 (15.91) | .86 |
| Thiazolidinediones (TZD) | 78 (6.00) | 28 (1.97) | 106 (3.90) | <.001 |
| Glucagon-like peptide-1 receptor antagonist (GLP-1 RA) | 56 (4.31) | 39 (2.74) | 95 (3.49) | .03 |
| Sodium glucose transporter-1 inhibitor (SGLT-2i) | 28 (2.16) | 20 (1.41) | 48 (1.76) | .14 |
| Meglitinide | 220 (16.94) | 311 (21.87) | 531 (19.51) | .001 |
| Calcium channel blocker (CCB) | 524 (40.34) | 592 (41.63) | 1116 (41.01) | .49 |
| Diuretic | 388 (29.87) | 412 (28.97) | 800 (29.40) | .61 |
| Angiotensin-converting enzyme (ACE) inhibitor | 666 (51.27) | 713 (50.14) | 1379 (50.68) | .56 |
| Angiotensin receptor blocker (ARB) | 349 (26.87) | 336 (23.63) | 685 (25.17) | .05 |
| Beta blocker | 376 (29.95) | 407 (28.62) | 783 (28.78) | .85 |
| Alpha blocker | 393 (30.25) | 455 (32.00) | 848 (31.17) | .23 |
| Aspirin | 393 (30.25) | 455 (32.00) | 848 (31.17) | .33 |
| Clopidogrel | 74 (5.70) | 76 (5.34) | 150 (5.51) | .69 |
| Statin | 959 (73.83) | 1111 (78.13) | 2070 (76.07) | .01 |
| Fibrate | 29 (2.23) | 32 (2.25) | 61 (2.24) | .98 |
| Ezetimibe | 26 (2.00) | 37 (2.60) | 63 (2.32) | .30 |
| Warfarin | 66 (5.08) | 79 (5.56) | 145 (5.33) | .58 |